
1. annu rev med. 2016;67:387-404. doi: 10.1146/annurev-med-091014-090848. epub 2015 
oct 23.

vaccination dengue: challenges current developments.

guy b(1), lang j(1), saville m(1), jackson n(1).

author information: 
(1)research development, sanofi pasteur, 69007 lyon, france; email:
bruno.guy@sanofipasteur.com.

dengue growing threat worldwide, development vaccine a
public health priority. completion active phase two pivotal
efficacy studies conducted asia latin america sanofi pasteur has
constituted important step. several approaches development,
and whichever technology used, vaccine developers face several challenges
linked particular nature etiology dengue disease. start our
review defining questions potential issues linked dengue pathology 
presenting main types vaccine approaches explored these
questions; candidates late stage clinical development. 
in second part review, focus sanofi pasteur dengue vaccine
candidate, describing steps research phase iii efficacy studies.
finally, discuss could next steps, vaccine
introduction, ensure vaccine provide best benefit an
acceptable safety profile identified target populations.

doi: 10.1146/annurev-med-091014-090848 
pmid: 26515983  [indexed medline]

